关键词： ACTs, artemisinin combination therapies ADCs, Acinetobacter-derived cephalosporinases AML, acute myeloid leukemia AMT, aminopterin BLs, β-lactamases BNCT, boron neutron capture therapy BNNPs, boron nitride nanoparticles BNNTs, boron nitride nanotubes Boron-containing compounds CEs, carboxylesterases CIA, collagen-induced arthritis COVID-19, coronavirus disease 2019 ClpP, casein protease P Covalent inhibitors GSH, glutathione HADC1, class I histone deacetylase HBV, hepatitis B virus HCV, hepatitis C virus HIV, human immunodeficiency virus LeuRS, leucyl-tRNA synthetase Linker components MBLs, metal β-lactamases MDR-TB, multidrug-resistant tuberculosis MERS, Middle East respiratory syndrome MIDA, N-methyliminodiacetic acid MM, multiple myeloma MTX, methotrexate Mcl-1, myeloid cell leukemia 1 Mtb, Mycobacterium tuberculosis NA, neuraminidase NS5B, non-nucleoside polymerase OBORT, oxaborole tRNA capture OPs, organophosphate PBA, phenylboronic acid PDB, Protein Data Bank PPI, protein–protein interaction Prodrug QM, quinone methide RA, rheumatoid arthritis ROS, reactive oxygen species SARS-CoV-2, syndrome coronavirus 2 SBLs, serine β-lactamases SERD, selective estrogen receptor downregulator SHA, salicyl hydroxamic acid SaClpP, Staphylococcus aureus caseinolytic protease P TB, tuberculosis TTR, transthyretin U4CR, Ugi 4-component reaction cUTI, complex urinary tract infection dCTPase, dCTPase pyrophosphatase

来  源：   DOI：10.1016/j.apsb.2021.01.010   PDF(Sci-hub)   PDF(Pubmed)

Abstract：
Various boron-containing drugs have been approved for clinical use over the past two decades, and more are currently in clinical trials. The increasing interest in boron-containing compounds is due to their unique binding properties to biological targets; for example, boron substitution can be used to modulate biological activity, pharmacokinetic properties, and drug resistance. In this perspective, we aim to comprehensively review the current status of boron compounds in drug discovery, focusing especially on progress from 2015 to December 2020. We classify these compounds into groups showing anticancer, antibacterial, antiviral, antiparasitic and other activities, and discuss the biological targets associated with each activity, as well as potential future developments.
摘要：
在过去的二十年中，各种含硼药物已被批准用于临床。更多的人目前正在临床试验中。对含硼化合物的兴趣日益增加是由于其与生物靶标的独特结合特性；例如，硼取代可用于调节生物活性，药代动力学特性，和抗药性。从这个角度来看,我们旨在全面回顾硼化合物在药物发现中的现状，特别关注2015年至2020年12月的进展。我们将这些化合物分为显示抗癌的组，抗菌，抗病毒，抗寄生虫和其他活动，并讨论与每个活动相关的生物目标，以及潜在的未来发展。
公众号